When drugs are cur

Therapeutic value "low" of anti-Alzheimer, strengthening of the bill on drug control, suspension of the investigation Mediator: Pharmacopoeia was the last one.

Failing grade for anti-Alzheimer drugs. The Transparency Committee of the High Authority for Health (HAS) has found a therapeutic benefit "weak" anti-Alzheimer drugs, but that opinion should remain without consequences for the reimbursement for patients with ALD (long-term illness) .
The commission concluded that the four drugs - Ebixa (Lundbeck), Aricept (Eisai), Exelon (Novartis Pharma), Reminyl (Janssen-Cilag) - had "an extremely small but not zero", at least for some patients, said yesterday the Chairman of the Committee, Gilles Bouvenot. Since the previous evaluation in 2007 which had considered the medical service rendered (SMR) drugs such as "significant" were reported serious adverse events, including "most concern" are cardiovascular disease, according to the HAS.

The commission recommended to limit the prescription of one year, with a reassessment at 6 months. Renewal beyond one year should be decided in multidisciplinary meeting.
Hardens the Senate bill on drug control. The new left-wing majority in the Senate yesterday tightened the bill on drug control, to prevent the repetition of a health scandal like the Mediator, in particular by introducing the possibility of group actions of the victims. Senators adopted an amendment authorizing associations of victims of a drug harmful to lead to court action group, then that will benefit all patients affected. The action group, common in the United States, does not exist in French law.
The survey Mediator suspended until December. The Supreme Court yesterday suspended until December 1 of the instructions being in Paris on the Mediator in the expectation that a new claim is settled in Paris grouping of the various components of the health scandal. One immediate consequence is the indefinite postponement of the convocation of Jacques Servier to the judge, scheduled on November 9. The CEO of Servier Laboratories was indicted Sept. 21 for deception and fraud.